Cystic fibrosis (CF) has seen a multitude of therapeutic advances targeting its downstream
effects. This has led to a steady increase in survival over the past few decades. The recent …

The advent of CFTR modulators, a genomic specific medication, revolutionized the treatment
of CF for many patients. However, given that these therapeutics were only developed for …

With the advent of such precision medicine, patient genotype is now highly relevant. Areas
of current unmet need include drugs to cover all mutation classes, increasing access to …

Remarkable advances in the management of individuals born with cystic fibrosis (CF) would
not have been realized without empiric trial and error by CF clinicians with treatments …

People with cystic fibrosis (CF) are living longer and healthier lives due to advances in
therapies, aimed at targeting the underlying pathophysiology and more recently at the …

Background Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are
disease‐modifying medications for cystic fibrosis (CF) and are shown to be efficacious for …

CFTR modulators promise to transform the therapeutic landscape in CF in a precision based
fashion. Areas of ongoing research include developing drugs for all mutation classes so that …

Understanding variability in cystic fibrosis (CF) health outcomes requires an understanding
of factors that go far beyond Cystic Fibrosis Transmembrane Receptor (CFTR) function …

After 25 years of intensive search, there is not yet a cure for cystic fibrosis (CF). However, the
quest has led to major breakthroughs in understanding the basic disease defect and …

Cystic fibrosis (CF) is an autosomal recessive condition caused by mutations in the gene
encoding the CF transmembrane conductance regulator (CFTR) protein [1]. CFTR plays a …